OIG: CMS could lower Medicare payment for 15 Part B drugs
In a report this week, the Department of Health and Human Services’ Office of Inspector General identified 15 drug codes that in third-quarter 2022 met the Centers for Medicare & Medicaid Services’ criteria for substituting a lower Medicare price for certain Part B drugs. This means CMS may substitute either the widely available market price or 103% of the Average Manufacturers Price, whichever is less, when pricing these drugs, rather than using Average Sales Price plus 6%. The report does not identify the 15 drug codes.
Related News Articles
Headline
The RAND Corporation May 13 released its latest hospital pricing report, which focuses on prices paid for care at the hospital and service-line level. In…
Perspective
Hospitals hold an extraordinary place in our society by offering comfort and caring to all who walk through their doors, regardless of ability to pay.While the…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…
Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2036, according to the latest annual report by the Medicare…
Headline
The departments of Health and Human Services, Labor, and the Treasury May 1 released a new process for resubmitting disputes under the No Surprises Act…
Headline
The AHA May 2 released a new report highlighting how hospitals and health systems continue to experience significant financial pressures that challenge their…